Pharmacy chain unit economics in India explained

Pharmacy chain unit economics is simply the maths of one store: what it sells, at what margin, to how many people, and what it costs to keep the shutter open. In India, a pharmacy is not one business but two sitting behind the same counter. One side sells medicines, where prices and margins are tightly governed. The other sells everything from baby care to supplements, where a chain has far more room to set its own margin. Reading a pharmacy P&L means separating these two engines before you judge anything.

What does a pharmacy chain actually sell?

Most organised pharmacy chains split sales into a few buckets. Prescription medicines (often called Rx) are dispensed against a doctor's prescription. Over-the-counter (OTC) medicines are sold without one. Then comes the front-of-store: wellness and nutrition, personal care, baby care, medical devices such as glucometers and BP monitors, and increasingly private-label products carrying the chain's own brand.

The split matters because each bucket behaves differently. A prescription sale is driven by a doctor, not by the store's marketing. A front-of-store sale is driven by shelf placement, staff suggestion and price. A private-label sale is driven by the chain's own sourcing. A store that looks busy may still be thin on profit if most of its sales are low-margin prescription fills.

Diagnostics is a growing adjacency. Point-of-care testing is spreading beyond labs; BabyCue, an Odisha-based healthtech startup, won a Rs 5 lakh first prize at the Tribal Business Conclave Open Grand Challenge for DiaCue, a rapid test for childhood diarrhoea, according to the company. The company says the test gives results in 15 to 20 minutes without complex lab equipment or cold-chain storage. For a pharmacy chain, tie-ups with such tests are a way to add a service revenue line and pull footfall, though the clinical claims are the company's.

How do trade margins and distributor discounts work?

In medicines, the retail price is printed on the pack, and the margin a chemist earns is largely a function of the trade margin structure and what the distributor offers. A distributor buys from the manufacturer, sells to the retailer, and the retailer sells at the maximum retail price (MRP). The gap between what the retailer pays the distributor and the MRP is the retailer's gross margin on that product.

On many scheduled medicines, trade margins are governed by rules that cap how much can be built into the price chain. That means a chain cannot simply raise the price of a medicine to improve its margin. What it can do is negotiate harder with distributors, buy in larger volumes, and earn scheme discounts, quantity rebates and expiry-linked credit terms. These are the levers that separate a well-run chain from a single-counter shop.

Two terms are worth knowing. Trade margin is the spread built into the product's price between cost and MRP. Distributor margin is the wholesaler's cut, which sits before the retailer's. A chain with scale can sometimes buy directly from the manufacturer or use a consolidated distributor, squeezing out a layer. That is a supply-chain gain, not a price change for the customer.

Why does private label change the profit picture?

Private label means products sold under the chain's own brand — paracetamol, cough syrup, multivitamins, sanitisers, baby wipes. Because the chain controls sourcing and branding, it can capture both the manufacturer's margin and the retailer's margin on the same pack. That is why private label is the single biggest lever on pharmacy chain unit economics in India.

But there is a catch. Private label works best in categories where the customer is not brand-loyal — basic analgesics, ORS, cotton and bandages, generic wellness. It works poorly where a doctor has written a specific brand on the prescription. A chain that pushes private label too hard on prescription-led categories risks losing the customer to the chemist next door.

For context on how own-brand and channel control shift margins, look outside pharmacy. Lenskart made blue-light filtering lenses standard at no extra charge from 12 November, according to the company, and reported India revenue of ₹1,668 crore in Q2 FY27, up 35.3% year on year. The lesson is that owning the product and the store lets a retailer decide where margin lives.

What do footfall and basket economics look like store by store?

Store-level profitability comes down to four numbers: footfall (how many customers walk in), conversion (how many buy), basket size (average bill) and gross margin per bill. Multiply them and you get gross profit per day. Subtract rent, staff, electricity, shrinkage (loss from expiry and theft), and you get store-level operating profit.

Pharmacies have a natural advantage and a natural problem. The advantage is repeat visits — chronic patients come back every month. The problem is that a large share of those visits are small, low-margin prescription fills. The fix is to raise basket size without hurting trust: attach a vitamin, a BP monitor, a baby product. Staff training and shelf layout do this work.

Location is the other half. A store near a clinic or hospital gets prescription footfall but may pay higher rent. A store inside a residential complex gets family footfall and more front-of-store sales. Both can work; the mix decides which.

What are the regulatory limits on where a pharmacy can earn?

This is the part founders and investors underrate. As general background, a pharmacy in India operates under drug regulations that govern who can own and run it, what must be stocked, how prescriptions are recorded and how scheduled medicines are sold. Many scheduled medicines are subject to price control, so the store cannot simply mark up. Advertising and claims on medicines are restricted under general rules, which limits how a chain markets its way to higher margin.

The practical effect: a chain's upside comes less from pricing medicines and more from (a) supply-chain efficiency, (b) front-of-store mix, (c) private label, and (d) services such as diagnostics tie-ups and home delivery. Any model that assumes it can raise medicine prices to improve margin is built on sand.

Common mistakes to avoid when reading a pharmacy P&L:

• Reading revenue without mix. Two chains with identical sales can have very different margins depending on prescription share.
• Ignoring expiry and returns. Medicines expire; unsold stock is a real cost that sits outside gross margin.
• Counting stores, not same-store growth. New stores flatter topline; mature-store sales tell you if the model works.
• Treating private label as free money. It needs shelf space, staff push and customer trust.
• Forgetting working capital. Distributor credit terms decide how much cash a chain needs to run.

What it means for Indian retailers

For a founder opening a pharmacy, the first job is to model the mix, not the topline. Work out what share of sales will be prescription, what share front-of-store, and what share private label. Then check whether the rent and staff cost can be covered at that blended margin. For an investor evaluating a chain, ask for same-store sales growth, private-label share, expiry as a percentage of purchases, and average distributor credit days. Those four numbers explain more about store-level profitability than any store count.

The wider retail lesson is familiar. D2C brands in India are stitching together owned stores, websites and third-party logistics to control costs, according to Miraggio and SNITCH executives. Pharmacy chains face the same choice: control the product and the shelf, or rent someone else's margin. The chains that own more of the stack — sourcing, brand, data on repeat customers — will earn more per square foot than those that only dispense.